Addressing these questions adequately will require multi-omic profiling of CDK4/6 inhibitor-treated cells, sophisticated genetic modeling in vitro and in vivo, and tumor single cell profiling, and the lessons learned will likely inform novel therapeutic combinations and our thinking on drug resistance. This evidence concerns the gene CDK4 and neoplasm.